头颈癌患者放化疗期间营养干预:HEADNUT随机试验结果
HEADNUT前瞻性随机试验纳入61例接受放化疗的头颈鳞癌患者,干预组每2周接受个体化营养咨询。结果显示,BMI<22 kg/m²且依从性好的干预组患者体重丢失少于对照组(p=0.015,CI:0.33-2.95);基线MUST筛查的敏感性和特异性分别为86%和88%;2年总生存率对照组70%、干预组79%(log-rank p=0.79)。
要点
- BMI<22 kg/m²的依从患者中,个体化营养咨询可减少体重丢失(p=0.015)。
- 基线MUST筛查检测营养不良的敏感性86%、特异性88%。
- 治疗前相位角、治疗后FFMI和白蛋白水平为总生存预后指标。
核心结论
- 营养不良对放化疗头颈癌患者结局产生负面影响。
- 基线相位角、治疗后FFMI和白蛋白水平可作为总生存的可靠指标。
研究设计与样本
- 干预组每2周接受个体化营养咨询,采用MUST、NRS-2002、Nutriscore问卷、临床检查、实验室分析和生物电阻抗分析评估营养状态。
主要发现
- 全体患者基线中位BMI为23.8(14.5-37.2)kg/m²,治疗结束后降至22.9(16.8-33)kg/m²(p<0.001)。
- 全体患者基线中位FFMI为18.1(14-24.7)kg/m²,治疗结束降至17.8(13.4-21.6)kg/m²(p<0.001)。
- BMI<22 kg/m²的依从患者中,干预组体重丢失少于对照组(p=0.015,CI:0.33-2.95)。
- 基线MUST是唯一同时具有良好敏感性(86%)和特异性(88%)的营养不良筛查工具。
- 中位随访15(1-26)个月,2年总生存率对照组70%、干预组79%(log-rank p=0.79)。
关键数值与推荐
- BMI<22 kg/m²的依从患者接受个体化营养咨询可减少体重丢失(p=0.015,CI:0.33-2.95)。
- 基线MUST筛查营养不良敏感性86%、特异性88%。
- 治疗前相位角、治疗后FFMI和白蛋白水平与总生存相关(log-rank p=0.002、p=0.008和p=0.016)。
临床怎么用
- 对接受放化疗的头颈癌患者应使用MUST进行营养不良筛查。
- 对BMI<22 kg/m²的患者可考虑每2周个体化营养咨询以减少体重丢失。
- 治疗前相位角、治疗后FFMI和白蛋白水平可用于总生存预后评估。
局限性
- 样本量61例,随访中位15个月且仍在进行中。
- 2年总生存率组间差异无统计学意义(log-rank p=0.79)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE/OBJECTIVE: Patients with squamous cell carcinoma of the head and neck undergoing (chemo-)radiotherapy are at high risk of malnutrition. Nevertheless, there is still a lack of prospective, randomized trials investigating the influence of nutritional status on therapy-related toxicity and patients' outcome. MATERIALS AND METHODS: Between October 2018 and October 2020, 61 patients were randomized into an intervention and control group. Questionnaires (MUST, NRS-2002, and Nutriscore), clinical examinations, laboratory analyses, and bioelectrical impedance analysis (BIA) were used to assess nutritional status for all patients at the beginning and end of therapy as well as every 2 weeks during therapy. The intervention consisted of an individualized nutritional counseling every 2 weeks during therapy. RESULTS: Median baseline BMI for all participants was 23.8 (14.5-37.2) kg/m2 and dropped to 22.9 (16.8-33) kg/m2 after therapy (p < 0.001). In all patients, median baseline fat-free mass index (FFMI) was 18.1 (14-24.7) kg/m2 and decreased to 17.8 (13.4-21.6) kg/m2 till the end of therapy (p < 0.001). Compliant patients with a BMI < 22 kg/m2 presented with less weight loss in the intervention group compared to the control (p = 0.015, CI: 0.33-2.95). At baseline, MUST was the only screening-test which showed both good sensitivity (86%) and specificity (88%) in detecting malnutrition. Median follow-up was 15 (1-26) months and is still ongoing. 2-year overall survival rate was 70% in the control and 79% in the intervention group (log-rank p = 0.79). Pretherapeutic phase angle, posttherapeutic FFMI and albumin level were prognostic indicators for overall survival (log-rank p = 0.002, p = 0.008 and p = 0.016). CONCLUSIONS: Malnutrition negatively impacts patients' outcome under (chemo-)radiotherapy. Baseline phase angle, posttherapeutic FFMI and albumin level are proposed as reliable indicators for overall survival. This study was registered within the German Clinical Trials Register (DRKS00016862).
引用
- Löser A, Abel J, Kutz LM, et al. Head and neck cancer patients under (chemo-)radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial. Radiother Oncol. 2021. PMID: 33766702. doi:10.1016/j.radonc.2021.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。